Navigation Links
Avastin under trial to test efficacy for pancreatic tumours!

Northwestern Memorial Hospital along with Northwestern University Feinberg School of Medicine is conducting a Phase II clinical trial to determine if avastin is effective in pancreatic tumours.//

The drug also known as bevacizumab is an anti-angiogenesis drug that is designed to inhibit the growth of blood vessels in tumours.

The test is being done to see that it in combination with abdominal radiation therapy and chemotherapy can reduce localized pancreatic tumours that have not metastasized or spread to other systems or organs in the body.

Northwestern Memorial is the sole clinical site where the research trial is being conducted.

"Our findings from the previous study suggest that the combination of chemotherapy and radiation is a safe and effective treatment method to reduce the local extent of pancreatic tumors," said Dr. Talamonti, MD, chief of the Division of Surgical Oncology at Northwestern Memorial Hospital, associate professor of surgery at Northwestern University Feinberg School of Medicine and co-investigator on the study

Another view was presented by William Small, Jr., MD, radiation oncologist, Northwestern Memorial Hospital, associate professor, Radiation Oncology, Northwestern University Feinberg School of Medicine and principal investigator for the trial, "The current study, which will be conducted over two years, will help us evaluate whether adding Avastin may also provide an effective combination to reduce the tumour and increase survival rates. Avastin is designed to inhibit Vascular Endothelial Growth Factor (VEGF), a protein that plays an important role in tumour angiogenesis or blood vessel formation, and maintenance of existing tumour vessels. By inhibiting VEGF, Avastin is thought to interfere with the blood supply to tumours, a process that is critical to tumour growth and metastasis.”

As per statistics by the American Cancer Society, pancreatic cancer is the fourth leading cause of cancer death among adults in America. Approximately 1 out of 4 patients with pancreatic cancer will live at least one year after the cancer is found.

Therefore it is very important that clinical trials are conducted and new viable solutions are found for this problem.


'"/>




Related medicine news :

1. Avastin, anti-Cancer Drug leads to Blindness and Other Complications
2. Warning on Avastin Updated
3. FDA Approval for Lung Cancer Treatment -Avastin Along with Chemotherapy
4. Cancer Drug Avastin Fights Brain Tumors too
5. Antioxidants protect health tissue in people undergoing radiation therapy.
6. How do babies understand language?
7. Doctor samples come under the ambit of advertisement
8. Latest device for cardiac revival under test
9. Heart disease in women being under-treated
10. Safety of soy under suspicion
11. Education in women brings sounder sleep
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic DNA ... many repetitive steps and often scientists require many different versions of DNA. Therefore, ... results in a lower error rate and cost saving for reagents and consumables. ...
(Date:3/29/2017)... , ... March 29, 2017 ... ... and South Hills of Pittsburgh now have easier access to the robotic-assisted ... by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the ... American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd ... Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar M. Stoney. ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Tuesday, March 28, ... American public to take the Diabetes Risk Test to find out if they are ... Angeles World Airports will light up the evening sky by programming the LAX pylons ...
(Date:3/28/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... ... ... adding another senior analyst to its award-winning team. Ruel Williamson brings his extensive ... Advisors, which has been a leader in the real estate valuation industry for ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017  Spiral Therapeutics, Inc. today announced ... Farma, S.L. for the worldwide exclusive rights to ... the field of otolaryngology for aggregate payments of ... The agreement provides Spiral with the option to ... product profile. Under the terms of the agreement, ...
(Date:3/29/2017)... 2017 NetworkNewsWire Editorial Coverage  ... There are a ... regulating marijuana, but economic arguments also favor its legalization. The ... enforcement costs. However, to legalize and regulate marijuana requires an ... (OTC: SING) ( SING Profile ), American Cannabis Company (OTC: ...
(Date:3/29/2017)... NEW YORK , March 29, 2017 ... ... cannabis market. According to a new report published by New Frontier ... by 2020. The accelerating pace of cannabis legalization in ... of legalizing cannabis, are considered to be a major factor that ...
Breaking Medicine Technology: